Details

Autor(en) / Beteiligte

• SEMENZATO, G
• FOA, R
• AGOSTINI, C
• ZAMBELLO, R
• TRENTIN, L
• VINANTE, F
• BENEDETTI, F
• CHILOSI, M
• PIZZOLO, G

Titel

High Serum Levels of Soluble Interleukin 2 Receptor in Patients With B Chronic Lymphocytic Leukemia

Ist Teil von

• Blood, 1987-08, Vol.70 (2), p.396-400

Ort / Verlag

Washington, DC: Elsevier Inc

Erscheinungsjahr

1987

Link zum Volltext

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• By using an enzyme-linked immunosorbent assay, the presence of the soluble form of the interleukin-2 receptor (slL-2R) was evaluated in the peripheral blood of 54 patients with B cell chronic lymphocytic leukemia (B-CLL). Serum levels of slL-2R were correlated with clinical features, relevant hematologic and immunological data, and in some cases, with in vitro functional studies. In 51 patients (94.4%), the levels of slL-2R were increased as compared with normal age-matched controls (1,781 U/mL ± 231 v 276 U/mL ± 26, respectively; P <. 001). Although this increase was observed in all stages of the disease and independently of several hematologic and immunologic parameters, a trend toward lower levels of slL-2R was documented in patients with a less-invasive disease. When the values were correlated with the functional status of the residual T cell population, it was found that patients with the lowest levels of slL-2R showed the best mitogenic response and helper capacity. It is suggested that in B-CLL patients the high levels of serum slL-2R, capable of binding to its ligand, may block the T cell-produced IL-2, thus contributing toward a defective physiological action by this lymphokine. In turn, this defective availability of IL-2 may play a part in the abnormal immunoregulation that is implicated in the hypogammaglobulinemia, susceptibility to infections, and incidence of second neoplasias often observed in this disease. © 1987 by Grune & Stratton, Inc. 0006-4971/87/7002-0009$3.00/0